Together, these considerations emphasise that the tumour type, the IDHMUT variant, and the type of in vitro model should be taken into account when studying synthetic lethal interactions with the IDH mutation, and that the underlying vulnerabilities may highly differ between tumour types that frequently harbour an IDH mutation. The gene discussed is IDH2; the disease is neoplasm.